Kier “Junior” Spates is hosting a new podcast to empower and educate people living with sickle cell disease. Called…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Health Canada has approved an extended-release formulation of Ferriprox (deferiprone) to treat iron overload in people with sickle cell…
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on FTX-6058, an experimental therapy that…
The risk of pregnancy-related death is about 26 times higher among people with sickle cell disease (SCD) in the…
We at Sickle Cell Anemia News have brought you coverage of the latest developments in research and advances in treatment related…
New preclinical data support the ability of the ESCAPE platform, an approach Beam Therapeutics is advancing, to more safely prepare people…
The experimental gene-editing therapy EDIT-301 appears to be working largely as expected in the first two sickle cell disease…
The Qatar Ministry of Public Health has approved Endari (L-glutamine) to treat adults and children, starting at age 5,…
A Phase 1b clinical trial testing the safety and pharmacological properties of the investigational oral medication FTX-6058 in people…
A gene editing platform developed by Cellectis called TALEN was able to restore healthy hemoglobin production in preclinical models of…